Screening was done by reviewing reference abstracts to exclude case reports, research in progress, conference abstracts, dissertations, books, and scientific meeting reports
0.6mg dose: 6.2% average weight loss 2.4mg dose: 12.5% average weight loss 3.6mg dose: 13.2% average weight loss 4.8mg dose: 14.9% average weight loss (planned treatment analysis) 4.8mg dose: 18.7% average weight loss (actual treatment received analysis) Placebo: 2.8% average weight loss The distinction between planned treatment and actual treatment received analyses matters
eligibility is confirmed during sign-up, but asking upfront saves time
Because the dose starts conservatively, most patients do not experience maximum weight loss effects until they reach the target dose of 2.4 mg per week, which typically happens around month 4 to 5
Timing should be treated as an unproven research practice, not a medical schedule
Semaglutide reduces food intake, which often reduces fluid consumption from foods